Sign in

    Madison Elsaadi

    healthcare equity research analyst at B. Riley Securities

    Madison El-Saadi, Ph.D., is a healthcare equity research analyst at B. Riley Securities, specializing in small- and mid-cap biotech companies in neuroscience, rare diseases, vaccines, and RNA-based therapeutics. He covers companies including Capricor Therapeutics, Eton Pharmaceuticals, Wave Life Sciences, and Ovid Therapeutics, and has generated notable results such as a 109% return on WAVE Life Sciences, a 63% return on Eton Pharmaceuticals, and maintains an approximate 66% success rate on stock calls. El-Saadi joined B. Riley in 2022 following prior equity research experience at Raymond James and completed a Ph.D. in neuropharmacology at Louisiana State University with postdoctoral work at McGovern Medical School and UT Health Science Center Houston. He holds advanced scientific credentials and is fully registered to provide equity research at the institutional level.

    Madison Elsaadi's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership

    Madison Elsaadi's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership • Q3 2025

    Question

    Madison Elsaadi asked if the obesity study's sample size is sufficient for statistical conclusions and what dosing frequency would be considered competitive for a muscle-sparing agent.

    Answer

    Management explained that the Phase 1 study is hypothesis-generating and not powered for statistical conclusions but will inform the design of future studies. They stated that the targeted quarterly to semi-annual dosing frequency is expected to be highly competitive in the market.

    Ask Fintool Equity Research AI

    Madison Elsaadi's questions to Eton Pharmaceuticals (ETON) leadership

    Madison Elsaadi's questions to Eton Pharmaceuticals (ETON) leadership • Q2 2025

    Question

    Madison Elsaadi asked for clarification on which products drove the significant revenue beat in the quarter and which are expected to drive growth in the second half of the year. She also requested more detail on the FDA's feedback regarding the Increlex label expansion, including the rationale for a new trial and the specific regulatory pathway.

    Answer

    CFO James Gruber responded that while product-specific revenue is not disclosed, the outperformance was heavily weighted toward Increlex, with Alkindi and Galzin also contributing to growth. CEO Sean Brynjelsen elaborated on the FDA feedback, explaining the proposed path is an open IND to collect U.S. clinical data on patients in the -2 to -3 standard deviation range, mirroring the European label. He expressed confidence in this approach and expects to gain agreement with the agency in Q4.

    Ask Fintool Equity Research AI